Bindellini, Davide http://orcid.org/0009-0000-0758-5951
Michelet, Robin http://orcid.org/0000-0002-5485-607X
Aulin, Linda B. S. http://orcid.org/0000-0003-4840-5704
Melin, Johanna http://orcid.org/0000-0002-5463-8398
Neumann, Uta http://orcid.org/0000-0003-3892-0577
Blankenstein, Oliver http://orcid.org/0000-0003-1803-5589
Huisinga, Wilhelm http://orcid.org/0000-0002-5249-3914
Whitaker, Martin J. http://orcid.org/0000-0003-2388-4753
Ross, Richard http://orcid.org/0000-0001-9222-9678
Kloft, Charlotte
Funding for this research was provided by:
Freie Universität Berlin
Article History
Received: 21 February 2024
Accepted: 30 June 2024
First Online: 8 July 2024
Declarations
:
: D.B., R.M., L.A. and M.J.W. have no conflict of interest. U.N. received a consultant and presentation fee from Diurnal Ltd., O.B. received a presentation fee from Diurnal Ltd., R.R. is a consultant to Neurocrine (Diurnal Ltd.). C.K. and W.H. report grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., Astra Zeneca, Boehringer Ingelheim Pharma GmbH & Co. K.G., F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk, and Sanofi) for the PharMetrX PhD program. C.K. reports an additional grant from the Innovative Medicines Initiative-Joint Undertaking (‘DDMoRe’), grants from the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (JPIAMR) and from the European Commission within in the Horizon 2020 framework programme (“FAIR”), all outside the submitted work.